Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19.
Eur J Gastroenterol Hepatol
; 34(2): 137-141, 2022 02 01.
Article
en En
| MEDLINE
| ID: mdl-33252418
ABSTRACT
INTRODUCTION:
Severe acute respiratory syndrome coronavirus-2 may escape the inactivation by gastric acid because of hypochlorhydria caused by proton pump inhibitors (PPIs), which could predispose the patients to severe COVID-19.METHODS:
We studied the association between prehospitalization PPI exposure and clinical outcomes among hospitalized COVID-19 patients.RESULTS:
A total of 295 hospitalized COVID-19 patients were included in the study. 15.6% of hospitalized COVID-19 patients were on PPIs at home. Mortality among PPI-users was 2.3 times higher than non-users, along with 2.3 times higher risk of acute respiratory distress syndrome after adjusting for confounding variables.CONCLUSION:
We found that prehospitalization PPI-exposure is independently associated with worse clinical outcomes, including mortality in COVID-19 patients, regardless of the presence of cardiovascular comorbidities.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Inhibidores de la Bomba de Protones
/
COVID-19
Límite:
Humans
Idioma:
En
Revista:
Eur J Gastroenterol Hepatol
Asunto de la revista:
GASTROENTEROLOGIA
Año:
2022
Tipo del documento:
Article